Search

Your search keyword '"Zelniker, Thomas A."' showing total 42 results

Search Constraints

Start Over You searched for: Author "Zelniker, Thomas A." Remove constraint Author: "Zelniker, Thomas A." Database Complementary Index Remove constraint Database: Complementary Index
42 results on '"Zelniker, Thomas A."'

Search Results

2. Coronary Angiography After Out-of-Hospital Cardiac Arrest Without ST-Segment Elevation: One-Year Outcomes of a Randomized Clinical Trial.

4. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.

6. Long‐term mortality after acute coronary syndromes among patients with normal, mildly reduced, or reduced ejection fraction.

7. A novel prediction model for pulmonary embolism: from dichotomizing algorithms to personalized likelihood.

8. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

9. Positionspapier Herzinsuffizienz und Diabetes.

10. Positionspapier Herzinsuffizienz und Diabetes.

11. Relationship of diabetes, heart failure, and N‐terminal pro‐B‐type natriuretic peptide with cardiovascular outcomes in patients with atrial fibrillation.

12. SGLT2 inhibitors in heart failure: insights from plasma proteomics.

13. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.

14. Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation.

15. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.

16. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

17. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58.

18. Relationship between markers of inflammation and hemodynamic stress and death in patients with out-of-hospital cardiac arrest.

21. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.

22. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.

23. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS.

25. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

26. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.

28. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials.

29. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry.

31. The prognostic value of right ventricular long axis strain in non-ischaemic dilated cardiomyopathies using standard cardiac magnetic resonance imaging.

32. Efficacy of enteral ticagrelor in hypothermic patients after out-of-hospital cardiac arrest.

33. Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias.

35. High-sensitive Troponin T increase after exercise in patients with pulmonary arterial hypertension.

36. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension.

38. Interruption of vascular endothelial growth factor receptor 2 signaling induces a proliferative pulmonary vasculopathy and pulmonary hypertension.

39. 244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial.

40. 236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial.

42. High-sensitive Troponin T increase after exercise in patients with pulmonary arterial hypertension.

Catalog

Books, media, physical & digital resources